Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
187.50
Oct 30 • 3:59 PM ET Dollar change-5.81 Percentage change(-3.01%)
Aftermarket Close
186.62
Aftermarket • 7:30 PM ET Dollar change-0.88 Percentage change(-0.47%)
Oct 29, 7:39 PMDaVita raises 2026 adjusted operating income, EPS and IKC guidance, narrows outlook as tech costs pressure dialysis margins
Index
S&P 500
Market Cap
11.79B
Enterprise Value
26.25B
Income
895.08M
Sales
14.17B
Book/sh
-9.32
Cash/sh
10.33
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
78000
IPO
Oct 31, 1995
P/E
14.18
Forward P/E
11.22
PEG
0.51
P/S
0.83
P/B
-
P/C
18.15
P/FCF
9.11
EV/EBITDA
9.22
EV/Sales
1.85
Quick Ratio
1.36
Current Ratio
1.41
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
13.22
EPS next Y
16.71
EPS next Q
4.26
EPS this Y
36.17%
EPS next Y
13.82%
EPS next 5Y
21.92%
EPS past 3/5Y
18.56% 8.29%
Sales past 3/5Y
5.53% 3.39%
EPS Y/Y TTM
36.05%
Sales Y/Y TTM
6.38%
EPS Q/Q
67.00%
Sales Q/Q
4.62%
Insider Own
2.08%
Insider Trans
-59.97%
Inst Own
92.71%
Inst Trans
-3.36%
ROA
5.06%
ROE
-
ROIC
7.31%
Gross Margin
27.35%
Oper. Margin
15.17%
Profit Margin
6.32%
SMA20
2.67%
SMA50
3.36%
SMA200
5.92%
Trades
Shs Outstand
63.40M
Shs Float
61.59M
52W High
247.49 -24.24%
52W Low
101.00 85.64%
Volatility
4.83% 3.45%
ATR (14)
7.29
RSI (14)
54.33
Beta
0.88
Rel Volume
2.20
Avg Volume
801.52K
Volume
1,760,644
Perf Week
2.10%
Perf Month
6.32%
Perf Quarter
-19.76%
Perf Half Y
23.64%
Perf YTD
65.04%
Perf Year
57.89%
Perf 3Y
144.65%
Perf 5Y
81.62%
Perf 10Y
239.92%
Prev Close
193.31
Price
187.50
Change %
-3.01%
Consensus
Buy
Avg. Price Target
$227.67
Implied Upside
+21.4%
Analysts11incl. previous ratings
Rating Distribution4 Buy · 6 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 07, 2026Upgrade
TD logoTTD Cowen
Hold → Buy$220+17.3%
May 06, 2026Upgrade
DB logoDDeutsche Bank
Hold → Buy$220+17.3%
Mar 06, 2024Initiated
BCS logoBBarclays
Equal Weight$133-29.1%
Aug 07, 2023Upgrade
UBS logoUUBS
Neutral → Buy$100 → $142-24.3%
Nov 01, 2022Downgrade
DB logoDDeutsche Bank
Buy → Hold$97 → $72-61.6%
Oct 31, 2022Downgrade
UBS logoUUBS
Buy → Neutral$117 → $74-60.5%
Aug 19, 2022Resumed
UBS logoUUBS
Buy$106 → $117-37.6%
Jun 21, 2022Reiterated
BAC logoBBofA Securities
Underperform$110 → $90-52.0%
Sep 10, 2021Initiated
CCowen
Market Perform$145-22.7%
Aug 12, 2021Downgrade
BCS logoBBarclays
Overweight → Equal Weight$135 → $146-22.1%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BERKSHIRE HATHAWAY INC10% OwnerOct 27 '26Sale180.43382,56369,026,03328,314,666Oct 29 05:21 PM
BERKSHIRE HATHAWAY INC10% OwnerJul 31 '26Sale199.55182,98036,513,29328,697,229Aug 04 05:27 PM
Waters Kathleen AlyceChief Legal & Pub. Affairs OffJun 15 '26Sale208.4015,4053,210,377109,194Jun 17 06:10 PM
Rodriguez JavierChief Executive OfficerJun 16 '26Sale209.2839,4078,247,018840,408Jun 17 06:09 PM
Rodriguez JavierChief Executive OfficerJun 15 '26Sale209.5030,0006,285,090879,815Jun 17 06:09 PM
Javier RodgriguezOfficerJun 16 '26Proposed Sale209.2839,4078,247,016Jun 16 04:44 PM
Kathleen WatersOfficerJun 15 '26Proposed Sale207.848,9501,860,202Jun 15 04:53 PM
Javier RodriguezOfficerJun 15 '26Proposed Sale209.5030,0006,285,102Jun 15 04:48 PM
Waters Kathleen AlyceOfficerJun 15 '26Proposed Sale207.936,4551,342,188Jun 15 04:10 PM
HEARTY JAMES OChief Compliance OfficerMay 14 '26Option Exercise110.635,784639,88441,737May 18 04:08 PM
HEARTY JAMES OChief Compliance OfficerMay 15 '26Sale193.9815,0002,909,74522,389May 18 04:08 PM
James HeartyOfficerMay 15 '26Proposed Sale193.9315,0002,908,950May 15 03:12 PM
Maughan David PaulChief Operating Officer, DKCMay 12 '26Sale199.2513,4562,681,16294,105May 13 04:10 PM
Maughan David PaulChief Operating Officer, DKCMay 11 '26Sale199.157,0731,408,581107,561May 13 04:10 PM
David MaughanOfficerMay 11 '26Proposed Sale198.0320,5294,065,340May 11 05:40 PM
ACKERMAN JOELCFO and TreasurerMay 07 '26Sale192.1051,4719,887,528132,434May 11 04:05 PM
HEARTY JAMES OChief Compliance OfficerMay 06 '26Sale174.872,184381,91635,953May 08 04:04 PM
Joel AckermanOfficerMay 07 '26Proposed Sale191.5051,4719,856,696May 07 04:43 PM
HEARTY JAMES OOfficerMay 06 '26Proposed Sale169.282,184369,708May 06 04:03 PM
BERKSHIRE HATHAWAY INC10% OwnerMay 01 '26Sale149.841,220,376182,864,67928,880,209May 05 06:52 PM
Waters Kathleen AlyceChief Legal & Pub. Affairs OffFeb 06 '26Option Exercise108.938,079880,045105,833Feb 09 06:57 PM
ACKERMAN JOELCFO and TreasuerFeb 06 '26Option Exercise108.9344,0654,800,000185,705Feb 09 06:56 PM
BERKSHIRE HATHAWAY INC10% OwnerJan 29 '26Sale120.561,658,480199,939,88130,100,585Feb 02 05:30 PM
HEARTY JAMES OChief Compliance OfficerDec 04 '25Option Exercise108.935,875639,96431,913Dec 05 04:35 PM
DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
CEO & Executive DirectorMr. Javier J. Rodriguez
CFO & TreasurerMr. Joel Ackerman
Chief Legal & Public Affairs OfficerMs. Kathleen Alyce Waters
Chief Compliance OfficerMr. James O. Hearty
Chief Operating Officer of DaVita Kidney CareMr. David P. Maughan